Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) will issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Parties that wish to listen to the company's conference call can do so using this link.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last released its quarterly earnings results on Thursday, March 28th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.06. On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Achieve Life Sciences Price Performance
Shares of NASDAQ ACHV traded up $0.17 during trading on Thursday, reaching $4.69. The company had a trading volume of 41,599 shares, compared to its average volume of 89,184. Achieve Life Sciences has a twelve month low of $3.03 and a twelve month high of $10.30. The stock has a market capitalization of $160.63 million, a PE ratio of -2.92 and a beta of 1.26. The stock has a 50-day moving average price of $4.45 and a two-hundred day moving average price of $4.44. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 4.02.
Analyst Ratings Changes
ACHV has been the subject of a number of analyst reports. Oppenheimer reissued an "outperform" rating and issued a $18.00 price target on shares of Achieve Life Sciences in a report on Monday, April 1st. Jonestrading started coverage on Achieve Life Sciences in a research note on Wednesday, April 17th. They issued a "buy" rating and a $20.00 target price for the company. Finally, Lake Street Capital dropped their target price on Achieve Life Sciences from $19.00 to $11.00 and set a "buy" rating for the company in a research note on Tuesday, March 5th.
Check Out Our Latest Stock Report on Achieve Life Sciences
About Achieve Life Sciences
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Recommended Stories
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
